Loading
A phase 2 trial of Durvalumab, Carboplatin, Cisplatin in small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of AZD2811 + Durvalumab in ES-SCLC is a phase 2 interventional study registered as NCT04745689 by AstraZeneca, with 31 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2022-06-18. Interventions recorded: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide. Conditions listed: Small-Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
31 enrolled.
95% CI 4.14 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-03-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS) in Maintenance Participants | AZD2811 + Durvalumab | 9 | 9.99 months | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Etoposide, Cisplatin, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Durvalumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/